Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ischemic Heart Disease

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 175 articles: HTML format

Single Articles

May 2024
1. ALBERS GW, Purdon B, Campbell BCV
   Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
   N Engl J Med. 2024;390:1729.
   PubMed    
   
   
   
2. GOYAL M, Bosshart SL, Ospel JM
   Tenecteplase for Stroke at 4.5 to 24 Hours.
   N Engl J Med. 2024;390:1729.
   PubMed    
   
   
   
3. GRINSPOON SK, Ribaudo HJ, Douglas PS
   Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
   N Engl J Med. 2024;390:1626-1628.
   PubMed    
   
   
   April 2024
4. STEG PG
   Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
   N Engl J Med. 2024;390:1434-1436.
   PubMed    
   
   
   
5. RAO SV
   Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
   N Engl J Med. 2024;390:1436-1438.
   PubMed    
   
   
   
6. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
   Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
   N Engl J Med. 2024;390:1382-1393.
   PubMed     Abstract available
   
   
   
7. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
   FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
   N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
   PubMed     Abstract available
   
   
   
8. KUNADIAN V
   Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
   N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
   PubMed    
   
   
   
9. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
   Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
   N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
   PubMed     Abstract available
   
   
   
10. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    PubMed     Abstract available
    
    
    
11. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
    Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
    PubMed     Abstract available
    
    
    
12. ROULEAU J
    Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
    PubMed    
    
    
    
13. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    PubMed     Abstract available
    
    
    
14. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    March 2024
15. WHITE HD
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:10.
    PubMed    
    
    
    
16. AL-LAMEE RK, Rajkumar CA
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:1151-1152.
    PubMed    
    
    
    
17. DURANTE A, Baiardo Redaelli M
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150-1151.
    PubMed    
    
    
    
18. SHERROD CF 4TH, O'Keefe EL, Ikemura N
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150.
    PubMed    
    
    
    
19. BESTERMANN WH JR
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1149-1150.
    PubMed    
    
    
    
20. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
    Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
    N Engl J Med. 2024;390:1030-1043.
    PubMed    
    
    
    
21. CARSON JL, Brooks MM, Hebert PC
    Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
    N Engl J Med. 2024;390:961-962.
    PubMed    
    
    
    
22. KHAN MS, Spertus JA, Chan PS
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960-961.
    PubMed    
    
    
    
23. CHAPALAIN X, Aubron C
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960.
    PubMed    
    
    
    
24. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
    Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
    N Engl J Med. 2024;390:900-910.
    PubMed     Abstract available
    
    
    February 2024
25. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    
    
    
    
26. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    
    
    
    
27. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
28. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
29. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    
    
    
    
30. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    
    
    
    
31. ALBERS GW, Jumaa M, Purdon B, Zaidi SF, et al
    Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
    N Engl J Med. 2024 Feb 8. doi: 10.1056/NEJMoa2310392.
    PubMed     Abstract available
    
    
    
32. LEIFER D
    Tenecteplase for Stroke - Opening the Window?
    N Engl J Med. 2024 Feb 8. doi: 10.1056/NEJMe2314930.
    PubMed    
    
    
    January 2024
33. SPATZ ES, Ginsburg GS, Rumsfeld JS, Turakhia MP, et al
    Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine.
    N Engl J Med. 2024;390:346-356.
    PubMed    
    
    
    
34. THIELE H, Desch S, Zeymer U
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:190-191.
    PubMed    
    
    
    
35. SCHOLZ KH, Meyer T
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:190.
    PubMed    
    
    
    
36. D'AMICO F, Pruna A, D'Andria Ursoleo J
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:190.
    PubMed    
    
    
    
37. BARDY T, Didier C, Mongardon N
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:189-190.
    PubMed    
    
    
    
38. STAHLI BE, Ruschitzka F
    Timing of Complete Revascularization for Myocardial Infarction. Reply.
    N Engl J Med. 2024;390:92.
    PubMed    
    
    
    
39. DEN DEKKER WK, Elscot JJ, Diletti R
    Timing of Complete Revascularization for Myocardial Infarction.
    N Engl J Med. 2024;390:91-92.
    PubMed    
    
    
    
40. OKHOTIN A, Barchuk A
    Timing of Complete Revascularization for Myocardial Infarction.
    N Engl J Med. 2024;390:91.
    PubMed    
    
    
    December 2023
41. BLOCH EM, Tobian AAR
    Optimizing Blood Transfusion in Patients with Acute Myocardial Infarction.
    N Engl J Med. 2023;389:2483-2485.
    PubMed    
    
    
    
42. WHITE HD
    Changing the Orbit around Percutaneous Coronary Intervention for Stable Angina.
    N Engl J Med. 2023;389:2387-2388.
    PubMed    
    
    
    
43. MAGNUSSEN C, Leong DP, Blankenberg S
    Modifiable Risk Factors and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2023;389:2401-2402.
    PubMed    
    
    
    
44. FIGTREE GA, Gray MP, Channon KM
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2401.
    PubMed    
    
    
    
45. MEI Z, Pu J, Zheng D
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2400-2401.
    PubMed    
    
    
    
46. OU D, Hu C, Huang S
    Modifiable Risk Factors and Cardiovascular Outcomes.
    N Engl J Med. 2023;389:2400.
    PubMed    
    
    
    November 2023
47. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Pitavastatin and Cardiovascular Disease in HIV. Reply.
    N Engl J Med. 2023;389:e46.
    PubMed    
    
    
    
48. OLALLA J, Pombo M
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    
    
    
    
49. IOANNOU P, Filippatos TD, Kofteridis DP
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    
    
    
    
50. ALAM SR, Mureithi M, Ferrand R
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    
    
    
    
51. BOETTIGER DC, Phillips AN, Newall AT
    Pitavastatin and Cardiovascular Disease in HIV.
    N Engl J Med. 2023;389:e46.
    PubMed    
    
    
    
52. BISCAGLIA S, Campo G
    Complete or Culprit-Only PCI in Older Patients with MI. Reply.
    N Engl J Med. 2023;389:1924.
    PubMed    
    
    
    
53. MONE P, Guerra G, Santulli G
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1923-1924.
    PubMed    
    
    
    
54. SANCHIS J, Ariza-Sole A, Alfonso F
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1923.
    PubMed    
    
    
    
55. DURAI V, Mallidi J
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1922.
    PubMed    
    
    
    
56. MADSEN JM, Engstrom T
    Complete or Culprit-Only PCI in Older Patients with MI.
    N Engl J Med. 2023;389:1922-1923.
    PubMed    
    
    
    
57. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    
58. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    
    
    
    
59. CARSON JL, Brooks MM, Hebert PC, Goodman SG, et al
    Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307983.
    PubMed     Abstract available
    
    
    
60. RAJKUMAR CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, et al
    A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2310610.
    PubMed     Abstract available
    
    
    October 2023
61. HOLM NR, Andreasen LN, Neghabat O, Laanmets P, et al
    OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions.
    N Engl J Med. 2023;389:1477-1487.
    PubMed     Abstract available
    
    
    
62. JONES WS
    Timing Is Everything - Evidence for When to Perform Complete Revascularization in STEMI.
    N Engl J Med. 2023;389:1427-1428.
    PubMed    
    
    
    
63. JOSEPH P, Yusuf S
    Coordinating Efforts to Reduce the Global Incidence of Cardiovascular Disease.
    N Engl J Med. 2023;389:1329-1331.
    PubMed    
    
    
    September 2023
64. BHASIN S, Lincoff AM, Nissen SE
    Cardiovascular Safety of Testosterone-Replacement Therapy. Reply.
    N Engl J Med. 2023;389:1150-1151.
    PubMed    
    
    
    
65. GROSSMANN M, Zajac JD
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1149-1150.
    PubMed    
    
    
    
66. MALOZOWSKI S, Reboussin DM
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1149.
    PubMed    
    
    
    
67. HUANG Y, Shen B, Zhou YF
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023;389:1148-1149.
    PubMed    
    
    
    August 2023
68. STAHLI BE, Varbella F, Linke A, Schwarz B, et al
    Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2307823.
    PubMed     Abstract available
    
    
    
69. ALI ZA, Landmesser U, Maehara A, Matsumura M, et al
    Optical Coherence Tomography-Guided versus Angiography-Guided PCI.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2305861.
    PubMed     Abstract available
    
    
    
70. BISCAGLIA S, Guiducci V, Escaned J, Moreno R, et al
    Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2300468.
    PubMed     Abstract available
    
    
    
71. MEHTA SR
    Complete Revascularization in Older Patients with Myocardial Infarction.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMe2307941.
    PubMed    
    
    
    
72. MAGNUSSEN C, Ojeda FM, Leong DP, Alegre-Diaz J, et al
    Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2206916.
    PubMed     Abstract available
    
    
    
73. THIELE H, Zeymer U, Akin I, Behnes M, et al
    Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2307227.
    PubMed     Abstract available
    
    
    
74. 
    Preventing HIV's Collateral Cardiovascular Damage.
    N Engl J Med. 2023;389:e11.
    PubMed    
    
    
    July 2023
75. GRINSPOON SK, Fitch KV, Zanni MV, Fichtenbaum CJ, et al
    Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
    N Engl J Med. 2023 Jul 23. doi: 10.1056/NEJMoa2304146.
    PubMed     Abstract available
    
    
    
76. FREIBERG MS
    HIV and Cardiovascular Disease - An Ounce of Prevention.
    N Engl J Med. 2023 Jul 23. doi: 10.1056/NEJMe2306782.
    PubMed    
    
    
    June 2023
77. NISSEN SE, Nicholls SJ, Lincoff AM
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2023;388:2489-2490.
    PubMed    
    
    
    
78. AMARENCO P
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488-2489.
    PubMed    
    
    
    
79. STEINACHER E, Sulzgruber P, Niessner A
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488.
    PubMed    
    
    
    
80. SPACEK L
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2488.
    PubMed    
    
    
    
81. LOPEZ-AYALA P, Glarner N, Mueller C
    Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes.
    N Engl J Med. 2023;388:2487-2488.
    PubMed    
    
    
    
82. LINCOFF AM, Bhasin S, Flevaris P, Mitchell LM, et al
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025.
    PubMed     Abstract available
    
    
    May 2023
83. LEE JM, Choi KH, Song YB, Lee JY, et al
    Intravascular Imaging-Guided or Angiography-Guided Complex PCI.
    N Engl J Med. 2023;388:1668-1679.
    PubMed     Abstract available
    
    
    April 2023
84. ISHANI A, Cushman WC, Leatherman SM
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. Reply.
    N Engl J Med. 2023;388:1342.
    PubMed    
    
    
    
85. FRAVEL MA, Ernst ME
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2023;388:1342.
    PubMed    
    
    
    
86. MESSERLI FH
    Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
    N Engl J Med. 2023;388:1341-1342.
    PubMed    
    
    
    March 2023
87. JABAGI MJ, Bertrand M, Botton J, Le Vu S, et al
    Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
    N Engl J Med. 2023 Mar 29. doi: 10.1056/NEJMc2302134.
    PubMed    
    
    
    
88. OLIVA-DAMASO N, Perazella MA
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2023;388:955.
    PubMed    
    
    
    
89. VAN REGEMORTER E, Jadoul M, Gillion V
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2023;388:954-955.
    PubMed    
    
    
    
90. KEANEY JF JR
    Bempedoic Acid and the Prevention of Cardiovascular Disease.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMe2300793.
    PubMed    
    
    
    
91. NISSEN SE, Lincoff AM, Brennan D, Ray KK, et al
    Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
    N Engl J Med. 2023 Mar 4. doi: 10.1056/NEJMoa2215024.
    PubMed     Abstract available
    
    
    January 2023
92. PERERA D, Ryan M, O'Kane PD
    PCI for Ischemic Left Ventricular Dysfunction. Reply.
    N Engl J Med. 2023;388:188-189.
    PubMed    
    
    
    
93. ALFONSO F, Cuesta J, Diez-Villanueva P
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:188.
    PubMed    
    
    
    
94. ANDREOTTI F, Chiariello GA, Massetti M
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:187-188.
    PubMed    
    
    
    
95. VIDAL-CALES P, Brugaletta S, Sabate M
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:187.
    PubMed    
    
    
    
96. DE SILVA K, Campbell T, Kumar S
    PCI for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2023;388:186-187.
    PubMed    
    
    
    December 2022
97. GUSEH JS 2ND, Parakh A, Chen YE, Sundt TM, et al
    Case 40-2022: A 38-Year-Old Man with Exertional Chest Discomfort.
    N Engl J Med. 2022;387:2450-2460.
    PubMed    
    
    
    
98. MC CAUSLAND FR, Singh AK, Claggett BL, Carroll K, et al
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
    N Engl J Med. 2022;387:2482-2485.
    PubMed    
    
    
    
99. HUANG C, He Y, Li Y
    Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
    N Engl J Med. 2022;387:2482.
    PubMed    
    
    
    
100. ROJAS-RIVERA J, Carriazo S, Ortiz A
     Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
     N Engl J Med. 2022;387:2481-2482.
     PubMed    
     
     
     
101. ISHANI A, Cushman WC, Leatherman SM, Lew RA, et al
     Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
     N Engl J Med. 2022 Dec 14. doi: 10.1056/NEJMoa2212270.
     PubMed     Abstract available
     
     
     
102. CASTELLANO JM, Cordero A, Fuster V
     Polypill Strategy in Secondary Cardiovascular Prevention. Reply.
     N Engl J Med. 2022;387:2197-2198.
     PubMed    
     
     
     
103. ZHANG Y, Zhu Z, Gao C
     Polypill Strategy in Secondary Cardiovascular Prevention.
     N Engl J Med. 2022;387:2197.
     PubMed    
     
     
     
104. CARNEY RM, Freedland KE
     Polypill Strategy in Secondary Cardiovascular Prevention.
     N Engl J Med. 2022;387:2197.
     PubMed    
     
     
     
105. STOSCHITZKY K
     Polypill Strategy in Secondary Cardiovascular Prevention.
     N Engl J Med. 2022;387:2196-2197.
     PubMed    
     
     
     November 2022
106. PARK DW, Kang DY, Park SJ
     Stress Testing in High-Risk Patients after PCI. Reply.
     N Engl J Med. 2022;387:e54.
     PubMed    
     
     
     
107. SHIOMI H
     Stress Testing in High-Risk Patients after PCI.
     N Engl J Med. 2022;387:e54.
     PubMed    
     
     
     
108. O'DONOGHUE ML, Rosenson RS, Gencer B, Lopez JAG, et al
     Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
     N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2211023.
     PubMed     Abstract available
     
     
     
109. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
     Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
     N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
     PubMed     Abstract available
     
     
     
110. 
     Application of High-Sensitivity Troponin in Suspected Myocardial Infarction.
     N Engl J Med. 2022;387:1724.
     PubMed    
     
     
     October 2022
111. DESAI AS, Dudzinski DM, Stib MT, Chen ST, et al
     Case 32-2022: A 76-Year-Old Man with Postoperative Cardiogenic Shock and Diffuse Rash.
     N Engl J Med. 2022;387:1502-1513.
     PubMed    
     
     
     
112. PERERA D, Clayton T, O'Kane PD, Greenwood JP, et al
     Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
     N Engl J Med. 2022;387:1351-1360.
     PubMed     Abstract available
     
     
     September 2022
113. 
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;387:1244.
     PubMed    
     
     
     
114. HONDA S, Kawasaki T
     Wellens' Syndrome.
     N Engl J Med. 2022;387:e25.
     PubMed    
     
     
     
115. RYDEN L, Standl E
     After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
     N Engl J Med. 2022;387:1136-1138.
     PubMed    
     
     
     
116. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
     Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
     N Engl J Med. 2022;387:1075-1088.
     PubMed     Abstract available
     
     
     
117. FUKAMACHI D, Okumura Y
     Giant Coronary-Artery Aneurysm.
     N Engl J Med. 2022;387:e23.
     PubMed    
     
     
     
118. PARK DW, Kang DY, Ahn JM, Yun SC, et al
     Routine Functional Testing or Standard Care in High-Risk Patients after PCI.
     N Engl J Med. 2022;387:905-915.
     PubMed     Abstract available
     
     
     
119. TAMIS-HOLLAND JE
     Surveillance Stress Testing "POST-PCI" - A Future Class III Recommendation?
     N Engl J Med. 2022;387:941-942.
     PubMed    
     
     
     
120. KOO BK, Hu X, Kang J, Zhang J, et al
     Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.
     N Engl J Med. 2022;387:779-789.
     PubMed     Abstract available
     
     
     August 2022
121. LINDHOLT JS, Sogaard R, Rasmussen LM, Mejldal A, et al
     Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.
     N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2208681.
     PubMed     Abstract available
     
     
     
122. CASTELLANO JM, Pocock SJ, Bhatt DL, Quesada AJ, et al
     Polypill Strategy in Secondary Cardiovascular Prevention.
     N Engl J Med. 2022 Aug 26. doi: 10.1056/NEJMoa2208275.
     PubMed     Abstract available
     
     
     
123. LESLIE BR, Gerwin LE
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;387:478.
     PubMed    
     
     
     
124. HEYMAN SN, Abassi Z
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;387:477-478.
     PubMed    
     
     
     
125. JACOBS DR JR, Sinaiko AR, Woo JG
     Childhood Risk Factors and Adult Cardiovascular Events. Reply.
     N Engl J Med. 2022;387:473-474.
     PubMed    
     
     
     
126. SCHUERMANS A, Lewandowski AJ
     Childhood Risk Factors and Adult Cardiovascular Events.
     N Engl J Med. 2022;387:473.
     PubMed    
     
     
     
127. WANG M, Zhou M, Feng Z
     Childhood Risk Factors and Adult Cardiovascular Events.
     N Engl J Med. 2022;387:472-473.
     PubMed    
     
     
     
128. ORTIZ A
     Childhood Risk Factors and Adult Cardiovascular Events.
     N Engl J Med. 2022;387:472.
     PubMed    
     
     
     July 2022
129. DODD JD, Kofoed KF, Dewey M
     CT or Invasive Coronary Angiography in Stable Chest Pain. Reply.
     N Engl J Med. 2022;387:379-380.
     PubMed    
     
     
     
130. GIBBONS RJ
     CT or Invasive Coronary Angiography in Stable Chest Pain.
     N Engl J Med. 2022;387:378.
     PubMed    
     
     
     
131. DANZI GB, Piccolo R
     CT or Invasive Coronary Angiography in Stable Chest Pain.
     N Engl J Med. 2022;387:378.
     PubMed    
     
     
     
132. BAUMANN AA, Roberts-Thomson RL, Psaltis PJ
     CT or Invasive Coronary Angiography in Stable Chest Pain.
     N Engl J Med. 2022;387:377-378.
     PubMed    
     
     
     
133. REDBERG R, Jeon D
     CT or Invasive Coronary Angiography in Stable Chest Pain.
     N Engl J Med. 2022;387:376-377.
     PubMed    
     
     
     June 2022
134. MA Y, Cook NR, Hu FB
     Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk. Reply.
     N Engl J Med. 2022;386:e60.
     PubMed    
     
     
     
135. IOANNOU A
     Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
     N Engl J Med. 2022;386:e60.
     PubMed    
     
     
     
136. LIU L, Chen Y, Liu S
     Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
     N Engl J Med. 2022;386:e60.
     PubMed    
     
     
     
137. INOUE K, Nishikawa T
     Daily Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
     N Engl J Med. 2022;386:e60.
     PubMed    
     
     
     May 2022
138. BRAUNWALD E
     Gliflozins in the Management of Cardiovascular Disease.
     N Engl J Med. 2022;386:2024-2034.
     PubMed    
     
     
     
139. FEARON WF, Zimmermann FM, Pijls NHJ
     Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. Reply.
     N Engl J Med. 2022;386:1865-1866.
     PubMed    
     
     
     
140. FERLINI M, Munafo A, Visconti LO
     Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
     N Engl J Med. 2022;386:1865.
     PubMed    
     
     
     
141. FELDMAN D, Nicolas J, Dangas G
     Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
     N Engl J Med. 2022;386:1864-1865.
     PubMed    
     
     
     
142. ROSENBLUM AL, Pack QR
     Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
     N Engl J Med. 2022;386:1864.
     PubMed    
     
     
     
143. VAN BELLE E, Patel M, Davies J
     Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
     N Engl J Med. 2022;386:1863-1864.
     PubMed    
     
     
     
144. YTTERBERG SR, Bhatt DL, Connell CA
     Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply.
     N Engl J Med. 2022;386:1768.
     PubMed    
     
     
     
145. D'AMICO F, Peyrin-Biroulet L, Danese S
     Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
     N Engl J Med. 2022;386:1767-1768.
     PubMed    
     
     
     
146. LADAK K, Crowther M
     Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
     N Engl J Med. 2022;386:1766-1767.
     PubMed    
     
     
     
147. OZDEDE A, Yazici H
     Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
     N Engl J Med. 2022;386:1766.
     PubMed    
     
     
     April 2022
148. PITT B, Joseph A, Schloemer P
     Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
149. ORTIZ A, Sarafidis P, Ferro CJ
     Cardiovascular Events with Finerenone in CKD and Diabetes.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
150. GERARD AO, Laurain A, Esnault VLM
     Cardiovascular Events with Finerenone in CKD and Diabetes.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
151. KAO PH, Hsu LC
     Cardiovascular Events with Finerenone in CKD and Diabetes.
     N Engl J Med. 2022;386:e43.
     PubMed    
     
     
     
152. INGELFINGER JR
     Childhood Risk Factors and Prediction of Adult Cardiovascular End Points.
     N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMe2203743.
     PubMed    
     
     
     
153. JACOBS DR JR, Woo JG, Sinaiko AR, Daniels SR, et al
     Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events.
     N Engl J Med. 2022 Apr 4. doi: 10.1056/NEJMoa2109191.
     PubMed     Abstract available
     
     
     March 2022
154. MAUROVICH-HORVAT P, Bosserdt M, Kofoed KF, Rieckmann N, et al
     CT or Invasive Coronary Angiography in Stable Chest Pain.
     N Engl J Med. 2022 Mar 4. doi: 10.1056/NEJMoa2200963.
     PubMed     Abstract available
     
     
     
155. DEVEREAUX PJ, Lamy A, Chan MTV, Allard RV, et al
     High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality.
     N Engl J Med. 2022;386:827-836.
     PubMed     Abstract available
     
     
     February 2022
156. PFEFFER MA, Jering KS, Braunwald E
     Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.
     N Engl J Med. 2022;386:603.
     PubMed    
     
     
     
157. IOANNOU A
     Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
     N Engl J Med. 2022;386:603.
     PubMed    
     
     
     January 2022
158. YTTERBERG SR, Bhatt DL, Mikuls TR, Koch GG, et al
     Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
     N Engl J Med. 2022;386:316-326.
     PubMed     Abstract available
     
     
     
159. FEARON WF, Zimmermann FM, De Bruyne B, Piroth Z, et al
     Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.
     N Engl J Med. 2022;386:128-137.
     PubMed     Abstract available
     
     
     December 2021
160. 
     Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
     N Engl J Med. 2021;385:2592.
     PubMed    
     
     
     
161. DESCH S, Freund A, Akin I, Behnes M, et al
     Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.
     N Engl J Med. 2021;385:2544-2553.
     PubMed     Abstract available
     
     
     
162. NEAL B, Tian M, Wu Y
     Salt Substitute and Cardiovascular Events and Death. Reply.
     N Engl J Med. 2021;385:2493-2494.
     PubMed    
     
     
     
163. BURSZTYN M
     Salt Substitute and Cardiovascular Events and Death.
     N Engl J Med. 2021;385:2493.
     PubMed    
     
     
     
164. MORITA H, Komuro I
     Salt Substitute and Cardiovascular Events and Death.
     N Engl J Med. 2021;385:2492-2493.
     PubMed    
     
     
     
165. ZUCCALA G, Laudisio A, Ciaburri M
     Salt Substitute and Cardiovascular Events and Death.
     N Engl J Med. 2021;385:2492.
     PubMed    
     
     
     
166. GRAUDAL N, Jurgens G, Alderman MH
     Salt Substitute and Cardiovascular Events and Death.
     N Engl J Med. 2021;385:2491-2492.
     PubMed    
     
     
     November 2021
167. MATHEW R, Di Santo P, Hibbert B
     Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. Reply.
     N Engl J Med. 2021;385:2108-2109.
     PubMed    
     
     
     
168. GIBSON LE, Chang MG, Berra L
     Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
     N Engl J Med. 2021;385:2108.
     PubMed    
     
     
     
169. POTTER BJ
     Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
     N Engl J Med. 2021;385:2107-2108.
     PubMed    
     
     
     
170. MA Y, He FJ, Sun Q, Yuan C, et al
     24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk.
     N Engl J Med. 2021 Nov 13. doi: 10.1056/NEJMoa2109794.
     PubMed     Abstract available
     
     
     
171. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
     Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
     N Engl J Med. 2021;385:1845-1855.
     PubMed     Abstract available
     
     
     
172. SINGH AK, Carroll K, McMurray JJV, Solomon S, et al
     Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
     N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113380.
     PubMed     Abstract available
     
     
     
173. SINGH AK, Carroll K, Perkovic V, Solomon S, et al
     Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
     N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113379.
     PubMed     Abstract available
     
     
     October 2021
174. VALGIMIGLI M, Frigoli E, Heg D, Tijssen J, et al
     Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
     N Engl J Med. 2021;385:1643-1655.
     PubMed     Abstract available
     
     
     
175. 
     Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
     N Engl J Med. 2021;385:1632.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.